Proportion of patients achieving ELF score changes ≥1
| 26 Weeks | 52 Weeks | 78 Weeks | |||||||
| GL | BIL | p Value* | GL | BIL | p Value* | GL | BIL | p Value* | |
| Type 1 diabetes | |||||||||
| N | 60 | 114 | 58 | 105 | 38 | 76 | |||
| ELF score change ≥1 | 0 (0.0) | 5 (4.4) | 0.081 | 1 (1.7) | 9 (8.6) | 0.089 | 1 (2.6) | 4 (5.3) | 0.520 |
| Type 2 diabetes, insulin-naïve | |||||||||
| N | 51 | 106 | 47 | 99 | 19 | 39 | |||
| ELF score change ≥1 | 1 (2.0) | 10 (9.4) | 0.105 | 2 (4.3) | 6 (6.1) | >0.999 | 0 (0.0) | 4 (10.3) | 0.292 |
| Type 2 diabetes, previously treated with insulin | |||||||||
| N | 48 | 104 | 47 | 101 | – | – | – | ||
| ELF score change ≥1 | 1 (2.1) | 9 (8.7) | 0.172 | 3 (6.4) | 14 (13.9) | 0.269 | – | – | – |
Data are presented as n (%).
No patients in any group at any time-point had an ELF score change ≥2.
↵*P values are for between-treatment comparisons at each time-point.
N, number of patients randomized; BIL, basal insulin peglispro; GL, insulin glargine; K-18, cytokeratin-18; ELF, enhanced liver fibrosis score; LFC, liver fat content; T1D, type 1 diabetes; T2D, type 2 diabetes.